title: Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
abstract: OBJECTIVE
  To compare the effect of intravitreal ranibizumab injections for the treatment of neovascular age-related macular degeneration between phakic and pseudophakic eyes.
  
  
  METHODS
  We retrospectively reviewed the medical records of 110 patients with neovascular age-related macular degeneration receiving intravitreal ranibizumab therapy and categorized them into 2 subgroups: phakic group (75 eyes) and pseudophakic group (45 eyes). For all patients, the initial three loading injections were performed by month, and reinjection was performed as needed. Main outcome measures included best-corrected visual acuity and central macular thickness as assessed by optical coherence tomography.
  
  
  RESULTS
  The mean age of the patients was 72 ± 4.2 years, and the patients were followed up for an average of 18 ± 3.6 months. At the last visit, the average number of injections was 3.87 ± 1.18 in the phakic group and 3.62 ± 1.17 in the pseudophakic group. After injection, the mean logarithm of the minimum angle of resolution of best-corrected visual acuity improved from 0.88 ± 0.65 to 0.75 ± 0.66 in the phakic group and from 0.86 ± 0.54 to 0.74 ± 0.09 in the pseudophakic group. Average central macular thickness decreased from 561 ± 289 μm to 419 ± 216 μm in the phakic group and from 559 ± 232 μm to 429 ± 166 μm in the pseudophakic group. There was no statistically significant difference in the injection number, best-corrected visual acuity improvement was achieved, and central macular thickness improvement was achieved between the phakic group and pseudophakic group.
  
  
  CONCLUSIONS
  The therapeutic effect of intravitreal ranibizumab injection for neovascular age-related macular degeneration did not show differences between phakic and pseudophakic eyes.
authors: Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea.
authors: Ji Sun
authors: JS
authors: Baek
authors: Han Joo
authors: HJ
authors: Cho
authors: Sung Won
authors: SW
authors: Cho
authors: Chul Gu
authors: CG
authors: Kim
authors: Jong Woo
authors: JW
authors: Kim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D007908:Lens, Crystalline / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D019591:Pseudophakia / Q000150:complications*; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D007208:Indocyanine Green; D000069579:Ranibizumab